While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
The solid-state battery race is heating up. Factorial Energy, a Massachusetts-based start-up, plans to go public in mid-2026. The listing will provide $100 million in capital to advance its battery ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...
Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results